Enhancement of the normal pancreas: comparison of manganese-DPDP and gadolinium chelate.
The purpose of this paper was to compare manganese-DPDP (Mn-DPDP) and gadolinium chelate (Gd-DTPA) contrast agents for enhancement of the normal pancreas. A total of 14 patients with focal liver disease underwent Mn-DPDP- and Gd-DTPA-enhanced 1.5 T MR examinations using spoiled gradient-echo (FLASH) technique at two separate times. Contrast agents were injected according to the currently recommended practices; Gd-DTPA was injected as a rapid bolus injection in a dosage of 0.1 mmol/kg, and Mn-DPDP was injected as a slow IV injection in a dosage of 5 mumol/kg. Quantitative region of interest measurements were made in 11 patients, and percent contrast enhancement of the pancreas and pancreas-fat signal-to-noise ratios (SNR) were determined for each agent. Images were also evaluated qualitatively by consensus reading of two investigators and overall scan quality was rated on a scale from 1 (poor) to 4 (very good). Enhancement of the pancreas immediately post Gd-DTPA was significantly higher than 15 min post Mn-DPDP (73.3 vs 36.3%; p = 0.003). On postcontrast images the pancreas-fat SNR measurements were 7.7 (i.e., pancreas higher in signal than fat) and -6.1 for Gd-DTPA and Mn-DPDP, respectively, which was significantly different (p < 0.001). Image quality was rated as 3.1 and 2.5 for Gd-DTPA- and Mn-DPDP-enhanced images, respectively. The normal pancreas enhances significantly more with Gd-DTPA than with Mn-DPDP administered under the conditions of this study. Overall image quality is also greater on the Gd-DTPA-enhanced images.
Kettritz
U
U
Department of Radiology, University of North Carolina, Chapel Hill 27599-7510, USA.
Warshauer
D M
DM
Brown
E D
ED
Schlund
J F
JF
Eisenberg
L B
LB
Semelka
R C
RC
D000273:Adipose Tissue / Q000033:anatomy & histology; D000328:Adult; D000368:Aged; D003287:Contrast Media / Q000008:administration & dosage; D004492:Edetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D005682:Gadolinium / Q000008:administration & dosage; D019786:Gadolinium DTPA; D006801:Humans; D007089:Image Enhancement; D007091:Image Processing, Computer-Assisted; D007275:Injections, Intravenous; D008107:Liver Diseases / Q000175:diagnosis; D008279:Magnetic Resonance Imaging; D008297:Male; D008345:Manganese / Q000008:administration & dosage; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage; D010179:Pancreas / Q000033:anatomy & histology*; D004369:Pentetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011732:Pyridoxal Phosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*
D003287:Contrast Media; D009942:Organometallic Compounds; D008345:Manganese; D011732:Pyridoxal Phosphate; D004369:Pentetic Acid; D004492:Edetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid